Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ITGAL | P20701 | 3/20 | 0.39 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.39 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14162998 | 0.80 | LMNA (0.44) | LMNARAB9ANPC1SMN1; SMN2GAA | |
| SCHEMBL8272180 | 0.80 | SMN1; SMN2 (0.61) | RAB9ANPC1SMN1; SMN2GAAL3MBTL1 | |
| SCHEMBL25365606 | 0.80 | HPGD (0.50) | LMNARAB9ANPC1SMN1; SMN2GAA | |
| SCHEMBL24089737 | 0.80 | HPGD (0.50) | LMNARAB9ANPC1SMN1; SMN2GAA | |
| SCHEMBL8271067 | 0.79 | ALDH1A1 (0.44) | RAB9ANPC1SMN1; SMN2GAAMAPT | |
| SCHEMBL27656999 | 0.79 | — | — | |
| SCHEMBL25237838 | 0.79 | MAPT (0.41) | LMNAGAAMAPTALDH1A1POLB | |
| SCHEMBL4862871 | 0.76 | LMNA (0.46) | LMNARAB9ANPC1SMN1; SMN2GAA | |
| SCHEMBL25367056 | 0.76 | CCR2 (0.43) | LMNARAB9ANPC1SMN1; SMN2GAA | |
| SCHEMBL8430099 | 0.76 | LMNA (0.40) | LMNARAB9ANPC1SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146811-A1 | Compounds and Methods For Treatment of Thrombosis | DAIICHI ASUBIO MEDICAL RESEARCH LABORATORIES LLC | 2008-06-19 | — | — | US | disclosed |
| WO-2006012504-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF THROMBOSIS | DAIAMED, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146811-A1 | Compounds and Methods For Treatment of Thrombosis | F2, SERPINC1, PLAT | LMNA 1855/4885RAB9A 2920/4885NPC1 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.